3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 2a
1
Lung Neoplasms
1
Lung Diseases
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Colonic Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Everolimus
19
lutetium Lu 177 dotatate
8
Octreotide
8
lanreotide
7
pasireotide
6
Temozolomide
6
Sunitinib
6
pembrolizumab
5
gallium Ga 68 dotatate
5
Positron Emission Tomography Computed Tomography
5
surufatinib
4
Sorafenib
4
Data Collection
4
Carboplatin
4
3-Iodobenzylguanidine
4
Positron-Emission Tomography
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Etoposide
3
Capecitabine
3
90Y-octreotide, DOTA-Tyr(3)-
3
pentetreotide
2
pazopanib
2
lenvatinib
2
fosbretabulin
2
fluorodopa F 18
2
cabozantinib
2
avelumab
2
arginyllysine
2
Single Photon Emission Computed Tomography Computed Tomography
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
pralsetinib
×
NET
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA